Exelixis Financial Statements
NASDAQ: EXELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Exelixis revenue and earnings
In fiscal 2025, Exelixis generated $2.32 billion in revenue, up 7.0% from fiscal 2024, its 9th consecutive year of revenue growth. Net income was $782.6 million (+50.1% year over year), for a net margin of 33.7% versus a median of 11.4% in the prior 5 years. Gross margin was 96.4% (down from 96.5%) and operating margin 37.6%.
Diluted earnings per share came in at $2.78, up from $1.76. Over the last 5 fiscal years, EXEL's revenue has grown at a 18.6% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Exelixis income statement (annual)
| Fiscal year (USD) | FY 20252026-01-02 | FY 20242025-01-03 | FY 20232023-12-29 | FY 20222022-12-30 | FY 20212021-12-31 | FY 20202021-01-01 | FY 20192020-01-03 | FY 20182018-12-28 | FY 20172017-12-29 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.32B | 2.17B | 1.83B | 1.61B | 1.43B | 987.54M | 967.77M | 853.83M | 452.48M | 191.45M |
| Revenue growth (YoY) | +6.98% | +18.49% | +13.60% | +12.27% | +45.31% | +2.04% | +13.35% | +88.70% | +136.34% | 0.00% |
| Cost of Revenue | 83.70M | 76.22M | 72.55M | 57.91M | 52.87M | 36.27M | 33.10M | 26.35M | 15.07M | 6.55M |
| Gross Profit | 2.24B | 2.09B | 1.76B | 1.55B | 1.38B | 951.27M | 934.68M | 827.48M | 437.41M | 184.90M |
| Operating Expenses | 1.36B | 1.49B | 1.59B | 1.35B | 1.10B | 841.21M | 598.30M | 414.97M | 286.57M | 219.58M |
| Research & Development | 825.00M | 910.41M | 1.04B | 891.81M | 693.72M | 547.85M | 336.96M | 182.26M | 112.17M | 95.97M |
| Selling, General & Admin | 518.73M | 492.13M | 542.71M | 459.86M | 401.71M | 293.36M | 228.24M | 206.37M | 159.33M | 116.14M |
| Operating Income | 872.19M | 604.62M | 170.88M | 201.48M | 286.67M | 110.06M | 369.47M | 438.86M | 165.91M | -28.12M |
| Interest Expense | — | — | — | — | — | — | 0 | 0 | 8.68M | 33.06M |
| Other Income (Expense) | -198.00K | -133.00K | 93.00K | -197.00K | -184.00K | 912.00K | 28.64M | 13.24M | -7.33M | -42.10M |
| Pretax Income | — | — | — | — | — | 130.84M | 398.11M | 452.09M | 158.58M | -70.22M |
| Income Tax | 158.64M | 160.37M | 49.76M | 52.07M | 63.09M | 19.06M | 77.10M | -237.98M | 4.35M | 0 |
| Net Income | 782.57M | 521.27M | 207.76M | 182.28M | 231.06M | 111.78M | 321.01M | 690.07M | 154.23M | -70.22M |
| Net Income growth (YoY) | +50.13% | +150.89% | +13.98% | -21.11% | +106.71% | -65.18% | -53.48% | +347.44% | — | — |
| EPS (Basic) | 2.88 | 1.80 | 0.65 | 0.57 | 0.73 | 0.36 | 1.06 | 2.32 | 0.52 | -0.28 |
| EPS (Diluted) | 2.78 | 1.76 | 0.65 | 0.56 | 0.72 | 0.35 | 1.02 | 2.21 | 0.49 | -0.28 |
| Shares Outstanding (Basic) | 271.57M | 290.03M | 318.15M | 321.53M | 314.88M | 308.27M | 302.58M | 297.89M | 293.59M | 250.53M |
| Shares Outstanding (Diluted) | 281.86M | 296.13M | 321.46M | 324.56M | 322.36M | 318.00M | 315.01M | 312.80M | 312.00M | 250.53M |
| EBITDA | 901.25M | 633.42M | 196.60M | 222.36M | 300.30M | 119.20M | 377.82M | 443.77M | 167.10M | -27.12M |
| Gross Margin | 96.39% | 96.49% | 96.04% | 96.41% | 96.32% | 96.33% | 96.58% | 96.91% | 96.67% | 96.58% |
| Operating Margin | 37.59% | 27.88% | 9.34% | 12.51% | 19.98% | 11.14% | 38.18% | 51.40% | 36.67% | -14.69% |
| Net Margin | 33.73% | 24.04% | 11.35% | 11.31% | 16.10% | 11.32% | 33.17% | 80.82% | 34.09% | -36.68% |
This table shows 10 annual periods of Exelixis's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow EXEL's reporting calendar. What is a income statement?